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Anthracycline antibiotics (ANTs) are important antineoplastic agents. One of them, 
daunorubicin (DAUN), is used for the treatment of acute leukaemia and other malignancies in 
children and adults. Factors limiting its clinical use include mainly resistance and 
cardiotoxicity. Enzymes from aldo-keto reductase (AKR) and short-chain 
dehydrogenase/reductase (SDR) superfamilies mediated the reduction of DAUN to its C-13 
alcohol metabolite daunorubicinol (DAUNOL). The metabolite is more cardiotoxic, less 
antineoplastic, and is causing anthracycline resistance. This diploma thesis aimed to examine 
the inhibitory effect of belinostat on the activity of AKR1A1, 1B1, 1B10, 1C3, and CBR1. The 
specific enzyme activity and inhibitory potential were estimated in vitro using recombinant 
enzymes, and the enzymatic production of DAUNOL was evaluated by the liquid 
chromatography (UHPLC) system. The inhibition was decreased in order AKR1C3  
AKR1B10  AKR1A1  AKR1B1  CBR1. The most inhibited enzyme, AKR1C3, expressed 
50,7% inhibition by 10M belinostat and 89,2% inhibition by 50M belinostat. In comparison 
with other similar publications, we can conclude that belinostat is relatively strong inhibitor 
against AKR1C3 (IC50 = 9,5  0,6 M, Ki = 8,9  0,4 and acts as a non-competitive one). Based 
on these findings, we can presume that the combination of DAUN and belinostat may 
potentially enhance the therapeutic effectiveness and safety of ANT via inhibition of AKR1C3. 
It can also be designed like a chemotherapeutic agent for many diseases associated with 
upregulation of AKR1C3. 
  
